MyPsoriasisTeam

Skyrizi (risankizumab-rzaa) is a biologic drug approved by the FDA for treating adults with moderate to severe plaque psoriasis. It works by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks, thus preventing the overproduction of IL-23 in the immune system.

Key Points about Skyrizi
- Show Full Answer

Skyrizi (risankizumab-rzaa) is a biologic drug approved by the FDA for treating adults with moderate to severe plaque psoriasis. It works by inhibiting interleukin (IL)-23, a chemical messenger involved in autoimmune attacks, thus preventing the overproduction of IL-23 in the immune system.

Key Points about Skyrizi:
- Administration: Subcutaneous injection every 12 weeks after initial loading doses.
- Common Side Effects: Upper respiratory infections, headache, fatigue, injection site reactions, and ringworm.
- Serious Side Effects: Increased risk for serious infections, including tuberculosis.

For more details, you can visit the Skyrizi website: [Skyrizi — AbbVie](https://www.skyrizi.com).

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Skyrizi (Risankizumab-rzaa) for Psoriasis | MyPsoriasisTeam

FDA Approves Skyrizi for Psoriatic Arthritis Following Promising Clinical Trials | MyPsoriasisTeam